Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ersodetug for tumor-associated hyperinsulinism with refractory hypoglycemia
NL-OMON58880Phase 3Recruiting
- Sponsor
- Rezolute, Inc.
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ersodetug in hyperinsulinism (HI) and apudoma (NET), sponsored by Rezolute, Inc. Primary endpoint: Proportion of participants with clinically meaningful reduction in glucose infusion rate from baseline. Started May 2026; status: recruiting.
02
Drugs
ersodetug
03
Conditions
hyperinsulinism (HI)apudoma (NET)
Beyond the preview
Go deeper on NL-OMON58880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58880.